The purpose of this study is to determine whether CCX282-B is effective in treating patients with moderate to severe Crohn's Disease.
Study acquired by Amgen and all disclosures were done by previous sponsor ChemoCentryx.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
436
CCX282-B or placebo capsules
Percentage of subjects achieving a clinical response (defined as a decrease from baseline in Crohn's Disease Activity Index [CDAI] score of at least 70) on Day 57
Time frame: Day 57
Percentage of subjects achieving clinical remission (defined as a Crohn's Disease Activity Index [CDAI] score less than or equal to 150) on Day 57
Time frame: Day 57
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Bankstown - Lidcombe Hospital
Bankstown, New South Wales, Australia
Royal Brisbane and Womens Hospital
Herston, Queensland, Australia
Royal Adelaide Hospital
Adelaide, South Australia, Australia
Flinders Medical Centre
Bedford Park, South Australia, Australia
Launceston General Hospital
Launceston, Tasmania, Australia
Box Hill Hospital
Box Hill, Victoria, Australia
St Vincents Hospital
Fitzroy, Victoria, Australia
Bayside Gastroenterology
Frankston, Victoria, Australia
Royal Melbourne Hospital
Parkville, Victoria, Australia
The Alfred Hospital
Prahran, Victoria, Australia
...and 102 more locations